Atea Pharmaceuticals (AVIR) Competitors $2.82 -0.12 (-4.08%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.82 +0.01 (+0.18%) As of 04/15/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, CMRX, CDMO, and RCUSShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Avid Bioservices Arcus Biosciences Syndax Pharmaceuticals (NASDAQ:SNDX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Do analysts prefer SNDX or AVIR? Syndax Pharmaceuticals presently has a consensus price target of $36.20, indicating a potential upside of 219.51%. Atea Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 112.77%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Syndax Pharmaceuticals is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation and earnings, SNDX or AVIR? Atea Pharmaceuticals has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M41.17-$209.36M-$3.73-3.04Atea PharmaceuticalsN/AN/A-$135.96M-$2.00-1.41 Does the media refer more to SNDX or AVIR? In the previous week, Atea Pharmaceuticals had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Atea Pharmaceuticals and 7 mentions for Syndax Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.65 beat Atea Pharmaceuticals' score of 0.16 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in SNDX or AVIR? 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer SNDX or AVIR? Syndax Pharmaceuticals received 372 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 65.38% of users gave Syndax Pharmaceuticals an outperform vote while only 47.50% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% Atea PharmaceuticalsOutperform Votes1947.50% Underperform Votes2152.50% Which has more volatility & risk, SNDX or AVIR? Syndax Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Is SNDX or AVIR more profitable? Atea Pharmaceuticals' return on equity of -34.90% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax PharmaceuticalsN/A -64.34% -57.72% Atea Pharmaceuticals N/A -34.90%-32.38% SummarySyndax Pharmaceuticals and Atea Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$241.18M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.366.7921.7317.82Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book0.425.866.464.00Net Income-$135.96M$141.86M$3.20B$247.23M7 Day Performance2.92%4.50%2.86%1.45%1 Month Performance-8.44%-12.65%-8.55%-6.24%1 Year Performance-24.60%-11.06%10.47%0.60% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals2.5157 of 5 stars$2.82-4.1%$6.00+112.8%-25.0%$241.18MN/A-1.3670SNDXSyndax Pharmaceuticals3.3478 of 5 stars$11.01-2.1%$36.20+228.8%-47.6%$947.34M$23.68M-3.03110Gap DownWVEWave Life Sciences4.1709 of 5 stars$5.80-3.8%$22.60+289.7%+9.4%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.0797 of 5 stars$27.38-2.7%$43.60+59.2%-22.8%$879.77M$631.45M11.80210Positive NewsGap DownELVNEnliven Therapeutics2.5632 of 5 stars$17.87-4.4%$38.75+116.8%-14.5%$875.70MN/A-9.4150News CoverageDYNDyne Therapeutics3.5747 of 5 stars$7.49-9.5%$47.46+533.7%-69.1%$847.28MN/A-2.10100GPCRStructure Therapeutics2.5757 of 5 stars$14.31-5.4%$81.29+468.0%-49.8%$820.58MN/A-19.34136News CoverageETNB89bio2.5885 of 5 stars$5.49-4.9%$27.56+401.9%-36.2%$801.45MN/A-1.8940Short Interest ↑News CoverageHigh Trading VolumeCMRXChimerix2.9082 of 5 stars$8.52-0.1%$8.53+0.2%+834.8%$799.21M$212,000.00-9.0690CDMOAvid Bioservices0.7966 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320High Trading VolumeRCUSArcus Biosciences2.4498 of 5 stars$7.28+5.9%$30.25+315.8%-50.9%$764.88M$258M-2.31500High Trading Volume Remove Ads Related Companies and Tools Related Companies Syndax Pharmaceuticals Alternatives Wave Life Sciences Alternatives Collegium Pharmaceutical Alternatives Enliven Therapeutics Alternatives Dyne Therapeutics Alternatives Structure Therapeutics Alternatives 89bio Alternatives Chimerix Alternatives Avid Bioservices Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
